Saidani M, Darle A, Jarrige M, Polveche H, El Kassar L, Julie S
Int J Mol Sci. 2023; 24(7).
PMID: 37047372
PMC: 10094141.
DOI: 10.3390/ijms24076398.
Tian J, Wang Y, Ding M, Zhang Y, Chi J, Wang T
Oxid Med Cell Longev. 2021; 2021:7617839.
PMID: 34745423
PMC: 8568525.
DOI: 10.1155/2021/7617839.
Lopez-Tejedor D, Claveria-Gimeno R, Velazquez-Campoy A, Abian O, Palomo J
Pharmaceuticals (Basel). 2021; 14(8).
PMID: 34451856
PMC: 8399381.
DOI: 10.3390/ph14080759.
Wang Y, Li S, Li C
Clin Rev Allergy Immunol. 2021; 61(3):299-323.
PMID: 34283349
DOI: 10.1007/s12016-021-08868-z.
Yi X, Cui T, Li S, Yang Y, Chen J, Guo S
Med Sci Monit. 2018; 24:6489-6497.
PMID: 30219821
PMC: 6154310.
DOI: 10.12659/MSM.910515.
Hearing loss in vitiligo: current concepts and review.
de Jong M, Adelman C, Gross M
Eur Arch Otorhinolaryngol. 2017; 274(6):2367-2372.
PMID: 28197707
DOI: 10.1007/s00405-017-4452-8.
Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients.
Cui T, Yi X, Guo S, Zhou F, Liu L, Li C
Sci Rep. 2016; 6:36360.
PMID: 27821860
PMC: 5099573.
DOI: 10.1038/srep36360.
Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.
Dey-Rao R, Sinha A
Genes Immun. 2015; 17(1):30-45.
PMID: 26562080
DOI: 10.1038/gene.2015.48.
Identification of tyrosinase inhibitors from traditional Chinese medicines for the management of hyperpigmentation.
Tang H, Chen Y
Springerplus. 2015; 4:184.
PMID: 25932370
PMC: 4411401.
DOI: 10.1186/s40064-015-0956-0.
The delicate balance of melanoma immunotherapy.
Gyorki D, Callahan M, Wolchok J, Ariyan C
Clin Transl Immunology. 2014; 2(8):e5.
PMID: 25505953
PMC: 4232053.
DOI: 10.1038/cti.2013.5.
Stability in Vitiligo: Is there a Perfect Way to Predict it?.
Sahni K, Parsad D
J Cutan Aesthet Surg. 2013; 6(2):75-82.
PMID: 24023428
PMC: 3764766.
DOI: 10.4103/0974-2077.112667.
Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study.
Ruiz-Arguelles A, Garcia-Carrasco M, Jimenez-Brito G, Sanchez-Sosa S, Perez-Romano B, Garces-Eisele J
Clin Exp Immunol. 2013; 174(2):229-36.
PMID: 23815517
PMC: 3828826.
DOI: 10.1111/cei.12168.
Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo.
Sanchez-Sosa S, Aguirre-Lombardo M, Jimenez-Brito G, Ruiz-Arguelles A
Clin Exp Immunol. 2013; 173(2):179-83.
PMID: 23607858
PMC: 3722918.
DOI: 10.1111/cei.12096.
Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation.
Jin Y, Ferrara T, Gowan K, Holcomb C, Rastrou M, Erlich H
J Invest Dermatol. 2012; 132(6):1730-3.
PMID: 22402439
PMC: 3513338.
DOI: 10.1038/jid.2012.37.
Nonsegmental vitiligo and autoimmune mechanism.
Oiso N, Suzuki T, Fukai K, Katayama I, Kawada A
Dermatol Res Pract. 2011; 2011:518090.
PMID: 21804820
PMC: 3144695.
DOI: 10.1155/2011/518090.
Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.
Agretti P, De Marco G, Sansone D, Betterle C, Coco G, Dimida A
J Endocrinol Invest. 2010; 33(11):784-8.
PMID: 20332705
DOI: 10.1007/BF03350342.
New treatment modalities for vitiligo: focus on topical immunomodulators.
Kostovic K, Pasic A
Drugs. 2005; 65(4):447-59.
PMID: 15733009
DOI: 10.2165/00003495-200565040-00002.
Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?.
Betterle C, Lazzarotto F, Presotto F
Clin Exp Immunol. 2004; 137(2):225-33.
PMID: 15270837
PMC: 1809126.
DOI: 10.1111/j.1365-2249.2004.02561.x.
Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.
Waterman E, Kemp E, Gawkrodger D, Watson P, Weetman A
Clin Exp Immunol. 2002; 129(3):527-32.
PMID: 12197895
PMC: 1906462.
DOI: 10.1046/j.1365-2249.2002.01949.x.
The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.
Kemp E, Waterman E, Hawes B, ONeill K, Gottumukkala R, Gawkrodger D
J Clin Invest. 2002; 109(7):923-30.
PMID: 11927619
PMC: 150932.
DOI: 10.1172/JCI14643.